CFA
SUPN icon

Carroll Financial Associates’s Supernus Pharmaceuticals SUPN Stock Holding History

Carroll Financial Associates’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-56
Closed -$1K – 1922
2021
Q3 		$1K Buy
+56
New +$1.5K ﹤0.01% 1712
2020
Q1 		– Sell
-150
Closed -$3K – 1661
2019
Q4 		$3K Hold
150
– – ﹤0.01% 1338
2019
Q3 		$4K Hold
150
– – ﹤0.01% 1245
2019
Q2 		$4K Hold
150
– – ﹤0.01% 1274
2019
Q1 		$5K Hold
150
– – ﹤0.01% 1119
2018
Q4 		$5K Buy
+150
New +$6.45K ﹤0.01% 1043

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Carroll Financial Associates's SUPN Position: Q4 2021 in Review

Carroll Financial Associates sold out of Supernus Pharmaceuticals (SUPN) in Q4 2021, closing a stake of 56 shares — an estimated $1K sold.

Carroll Financial Associates first reported a position in SUPN in Q4 2018 and held it in 6 quarters. The position peaked at $5K in Q1 2019. 235 funds tracked by Wall St. Rank hold SUPN as of Q4 2021.

  • Carroll Financial Associates reported no remaining Supernus Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Carroll Financial Associates sold 56 Supernus Pharmaceuticals shares in Q4 2021, an estimated $1K.
  • Carroll Financial Associates first reported a position in Supernus Pharmaceuticals in Q4 2018 and held it in 6 quarters.
  • Carroll Financial Associates's Supernus Pharmaceuticals position peaked at $5K in Q1 2019.
  • 235 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.